Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.
News & Analysis: Cellectis
The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.
The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
Despite getting passed along to a biotech start-up, Cellectis could have a bright future.
Belldegrun's Allogene Therapeutics has just inked a transformative deal to land Pfizer's CAR-T cancer gene therapy program.
Find out why these stocks missed out on the rally.
On a day when markets in general headed lower on macro-level fears, these shares lead the way down due to more company-specific issues.
The biopharma became the latest in the CAR-T space to receive a clinical hold from the FDA.
Gene editing appears poised to usher in a brave new world for biotech.
Here are four stocks we're watching closely.